Managing Erythrocytosis / Elevated Hematocrit on Testosterone Cypionate: The HealthRX.com Step-by-Step Protocol

Why testosterone cypionate raises hematocrit

The Depo-Testosterone label says androgens have been reported to stimulate production of red blood cells by enhancing production of erythropoietic stimulation factor, and lists polycythemia among its adverse reactions [2].

The size of the effect depends partly on formulation. In a network meta-analysis of 29 placebo-controlled randomized trials with 3,393 men, intramuscular testosterone enanthate/cypionate raised mean hematocrit by 4.0% versus placebo (95% CI 2.9 to 5.1) [1]. Gel raised it by 3.0% (1.8 to 4.3), patch by 1.4% (0.2 to 2.6), oral testosterone undecanoate by 4.3% (0.7 to 8.0), and intramuscular testosterone undecanoate by 1.6% (0.3 to 3.0) [1]. Intramuscular enanthate/cypionate raised hematocrit significantly more than patch; the other pairings were not significantly different [1].

Rates vary widely by population and by how erythrocytosis is defined. A systematic review of 45 studies found erythrocytosis rates up to 66.7% in men on prescription testosterone, with intramuscular formulations, higher doses and older age associated with higher risk, and thromboembolic events in up to 2.7% of men on testosterone therapy [4]. A retrospective review of 178 hypogonadal men followed for 3 years found hematocrit above 50% in 66.7% of men on injectable testosterone, 12.8% on gels and 35.1% on pellets; the injection group was younger and had higher baseline hematocrit, and the study was not randomized [8]. A 2018 review describes short-acting injectable formulations as having the highest incidence of erythrocytosis [9].

What hematocrit level needs action?

A 2023 clinical consultation guide in European Urology Focus says providers should decrease or discontinue testosterone therapy when hematocrit exceeds 54%, until the hematocrit normalizes [3]. The 2018 Endocrine Society guideline recommends against starting testosterone in men with elevated hematocrit and recommends monitoring hematocrit during the first year of therapy [5].

The Depo-Testosterone label says to check hemoglobin and hematocrit periodically in long-term use and notes that increased red blood cell mass may raise thromboembolic risk [2].

A 2022 review notes that evidence for harm from secondary erythrocytosis during testosterone therapy is scarce and that the hematocrit cutoffs in multiple guidelines appear arbitrarily chosen [10].

How an elevated hematocrit is assessed

Relative erythrocytosis from volume contraction is one reason a hematocrit can look high, and a historical overview of hematocrit and hemoglobin helps separate longstanding from newly acquired erythrocytosis [6]. The foremost step in the workup is excluding polycythemia vera with JAK2 mutation screening (exons 12 to 15) [6][7]. Serum erythropoietin is variably informative [6].

Does switching from injections to gel change it?

In the network meta-analysis, intramuscular enanthate/cypionate raised mean hematocrit by 4.0% and gel by 3.0%, and the difference between those two was not statistically significant [1]. A retrospective review found much lower erythrocytosis rates with gels than injections, but it was not randomized and the injection group began with higher hematocrit [8].

When phlebotomy may be considered

A 2025 hematology review of JAK2 wild-type erythrocytosis, which is not specific to testosterone, states that there are currently no evidence-based treatment guidelines, and that low-dose aspirin and/or phlebotomy (with frequency determined by symptom relief) might be considered on an individualized basis in the presence of hyperviscosity symptoms, cardiovascular comorbidities and/or a history of thrombosis, with cardiovascular risk factors controlled aggressively in everyone [7].

What the label says about clots

The Depo-Testosterone label says venous thromboembolic events, including deep vein thrombosis and pulmonary embolism, have been reported with testosterone products. It says to evaluate leg pain, swelling, warmth and redness for DVT and acute shortness of breath for PE, and that if a venous thromboembolic event is suspected, treatment with testosterone cypionate should be discontinued and an appropriate workup and management begun [2].

The link between testosterone-related erythrocytosis and thromboembolic events remains unclear; reviews describe the evidence as limited or inconclusive [9][11].